iMedicor Selected By iHealth Trust To Provide Secure Communications Services To Houston And Gulf Coast Region

NANUET, N.Y., April 11, 2013 -- iMedicor (OTC: VMCI) today announced that it had been chosen by iHealthTrust, a Houston-based Federally funded Health Information Exchange (HIE) serving a market of some 12,000 physicians and hospitals in the Houston and Gulf coast regions, to provide them with secure communications services via the iMedicor SocialHIE platform.

iMedicor's marketing partner, Galaxy Health Network, a managed care provider organization comprising 400,000 physicians, 2,700 medical centers and 47,000 ancillary care facilities nationwide, will support the iMedicor program via outreach services to Galaxy members in the Houston/Gulf Coast region.

Revenue from the program will likely begin in the second quarter of 2013, said iMedicor.

"We are pleased to have secured yet another opportunity to market our SocialHIE service," said iMedicor CEO, Fred Zolla. "We are also proud to be working with iHealthTrust, which is funded by the Office of the National Coordinator for Health Information Technology (ONC) – the principal Federal entity charged with coordinating the nationwide program to implement the electronic exchange of health information."

Manfred Sternberg, Chairman and Founder of iHealthTrust, added, "After a lengthy period of evaluating many different HIE systems, we are extremely excited to have selected iMedicor's new SocialHIE platform.  We believe the healthcare providers and healthcare facilities in the Houston and Gulf Coast region will now enjoy unparalleled communications services, which will also provide innumerable health benefits to the many patients they serve."

About iMedicor

iMedicor (http://www.imedicor.com/) is a provider of comprehensive healthcare communications solutions that enable physicians and other healthcare professionals to optimize the use of technology in managing their practices and participating in the federally-mandated transition from paper to Electronic Health Records (EHRs). Through two primary services, iMedicor offers low-cost, easy-to-adopt solutions that can be tailored to the needs of individual practices or larger organizations:

  • SocialHIE, the first information exchange platform to offer secure messaging services within a social/professional networking architecture. SocialHIE enables any physician, clinic or hospital to transmit and share information such as patient data, test results and images within a secure, HIPAA-compliant environment – and even between disparate EHR systems. SocialHIE also offers additional advantages such as community development, the ability to create private healthcare information exchange networks with patient specific information, and access to a vast catalog of accredited continuing medical education (CME) programs.
  • Meaningful Use Consulting Services. iMedicor is qualified to assist both primary care and specialist practices with EHR adoption and to help them attain Meaningful Use and receive incentive payments from the Federal Government for their compliance.

For investor information, please go to http://www.ir-site.com/imedicor/default.asp .

About iHealthTrust

The iHealthTrust is the Greater Houston area's Health Information Exchange (HIE).  iHealth Trust is a 501 (c) 3 nonprofit corporation owned and controlled by the greater Houston area community. Its mission is to deliver high quality, cost-effective healthcare for all Houstonians by utilizing electronically collected information, serving as a fiduciary for the consumer of that information.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.